LVTX
Price:
$0.9752
Market Cap:
$25.64M
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody...[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
LVTX
According to LAVA Therapeutics N.V.’s latest financial reports and current stock price. The company's current ROE is -62.22%. This represents a change of 253.49% compared to the average of -17.60% of the last 4 quarters.
The mean historical ROE of LAVA Therapeutics N.V. over the last ten years is -93.37%. The current -62.22% ROE has changed -33.37% with respect to the historical average. Over the past ten years (40 quarters), LVTX's ROE was at its highest in in the June 2020 quarter at 231.21%. The ROE was at its lowest in in the June 2019 quarter at -167.97%.
Average
-93.37%
Median
-82.02%
Minimum
-170.12%
Maximum
-31.56%
Discovering the peaks and valleys of LAVA Therapeutics N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 121.16%
Maximum Annual ROE = -31.56%
Minimum Annual Increase = -81.45%
Minimum Annual ROE = -170.12%
Year | ROE | Change |
---|---|---|
2023 | -82.02% | 121.16% |
2022 | -37.08% | 17.49% |
2021 | -31.56% | -81.45% |
2020 | -170.12% | 16.44% |
The current ROE of LAVA Therapeutics N.V. (LVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-50.22%
5-year avg
-93.37%
10-year avg
-93.37%
LAVA Therapeutics N.V.’s ROE is greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Miromatrix Medical Inc. (-70.01%), less than ZIVO Bioscience, Inc. (618.61%), greater than Bionomics Limited (-116.12%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Design Therapeutics, Inc. (-18.01%), greater than Xilio Therapeutics, Inc. (-214.74%), less than Eliem Therapeutics, Inc. (0%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Rezolute, Inc. (-69.83%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Instil Bio, Inc. (-37.44%), greater than Achilles Therapeutics plc (-54.57%), greater than NextCure, Inc. (-62.50%), greater than Assembly Biosciences, Inc. (-121.46%),
Company | ROE | Market cap |
---|---|---|
-184.40% | $42.01M | |
-24.20% | $76.07M | |
-70.01% | $92.95M | |
618.61% | $78.37M | |
-116.12% | $789.08M | |
-26.83% | $2.80B | |
-39.59% | $73.83M | |
-18.01% | $359.54M | |
-214.74% | $50.55M | |
0% | $342.68M | |
-90.19% | $75.07M | |
-50.10% | $85.89M | |
-47.95% | $193.98M | |
-69.83% | $255.53M | |
-57.63% | $40.64M | |
-104.85% | $71.47M | |
-64.55% | $57.32M | |
-42.26% | $726.61M | |
-42.45% | $273.18M | |
-8.54% | $8.20M | |
-37.44% | $142.85M | |
-54.57% | $46.85M | |
-62.50% | $24.31M | |
-121.46% | $93.56M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LAVA Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LAVA Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is LAVA Therapeutics N.V.'s ROE?
How is the ROE calculated for LAVA Therapeutics N.V. (LVTX)?
What is the highest ROE for LAVA Therapeutics N.V. (LVTX)?
What is the 3-year average ROE for LAVA Therapeutics N.V. (LVTX)?
What is the 5-year average ROE for LAVA Therapeutics N.V. (LVTX)?
How does the current ROE for LAVA Therapeutics N.V. (LVTX) compare to its historical average?